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CORRIGENDUM
Following relevant reader’s comments and Editor’s request, my co-authors and I would like to add
some references which have been unintentionally omitted in some sections of the review.We thank
the readers and the Editorial Office for pointing this out and helping us to improve the manuscript.
“INTRODUCTION SECTION” (PAGE 2)
After surgery, radiation therapy (RT) has long been an integral component of cancer care. It is
usually employed to locally eradicate tumor cells as well as alter tumor stroma with either curative
or palliative intent (Hodge et al., 2012; Kwilas et al., 2012).
Therefore, current efforts have been focusing on understanding the molecular, cellular, and
systemic processes driving cancer initiation, progression, heterogeneity, and metastatic spread
(Ramos and Bentires-Alj, 2015; Semenova et al., 2015).
As a major part of the tumor ECM, type I collagen exhibits high density and altered architecture
in malignant cancer and is causally linked to tumor formation and metastasis (Ren et al., 2014).
Until recently, these effects on tumor cells were exclusively attributed to integrins, a major class
of receptors that mediate cell interactions with extracellular matrix components. The identification
of the Discoidin Domain Receptor (DDR) family as collagen receptors represents a new paradigm
in the regulation of collagen-cell interactions and regulation of tumor progression (Marquez and
Olaso, 2014).
DDR1 and DDR2 were initially discovered by homology cloning based on their catalytic kinase
domains and were orphan receptors until 1997 when Shrivastava and co-workers and Vogel and
co-workers, reported that different types of collagen are functional ligands for these receptors
(Leitinger, 2014).
In contrast with classical growth factor tyrosine kinase receptors such as the epithelial growth
factor receptor (EGFR) and fibroblast growth factor receptor (FGFR) which display a rapid and
transient activation, DDR1 and DDR2 are unique in that they exhibit remarkably delayed and
sustained receptor phosphorylation upon binding to collagen (Iwai et al., 2013).
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Furthermore, many classical tyrosine kinase
receptors (RTKs) undergo negative regulation such as
receptor/ligand internalization and subsequent degradation
or dephosphorylation by phosphatases (Fu et al., 2013).
In addition, they are uniquely positioned to function as
sensors for ECM and to regulate a wide range of cell functions
such asmigration, cell proliferation, cytokine secretion, and ECM
homeostasis/remodeling (Borza and Pozzi, 2014).
“STRUCTURE, FUNCTION AND
REGULATION OF DDRS”
SECTION (PAGE 3)
DDRs control important aspects of cell behavior including
proliferation, migration, adhesion, and ECM remodeling but
are dysregulated in various human diseases. They are both
activated by several types of collagen. However, this activation
strictly requires collagen to be in its native and triple-helical
conformation. Heat-denatured collagen is not recognized by
DDRs (Valiathan et al., 2012; Carafoli and Hohenester, 2013).
Surprisingly, the substitution of five peripheral
amino acids in DDR2 with their DDR1 counterparts
converts DDR2 into a receptor of type IV collagen
(Carafoli and Hohenester, 2013).
AUTHOR CONTRIBUTIONS
All authors contributed to the designing, writing and the
validation of the last version of the manuscript.
FUNDING
This work was supported by grants from Ligue Contre le
Cancer 2015 (CCIR Grand-Est). CS is recipient of PhD
fellowships from the French Ministry of Higher Education and
Research.
REFERENCES
Borza, C. M., and Pozzi, A. (2014). Discoidin domain receptors in disease.Matrix
Biol. 34, 185–192. doi: 10.1016/j.matbio.2013.12.002
Carafoli, F., and Hohenester, E. (2013). Collagen recognition and transmembrane
signalling by discoidin domain receptors. Biochim. Biophys. Acta 1834,
2187–2194. doi: 10.1016/j.bbapap.2012.10.014
Fu, H. L., Valiathan, R. R., Arkwright, R., Sohail, A., Mihai, C., Kumarasiri,
M., et al. (2013). Discoidin domain receptors: unique receptor tyrosine
kinases in collagen-mediated signaling. J. Biol. Chem. 288, 7430–7437. doi:
10.1074/jbc.R112.444158
Hodge, J. W., Ardiani, A., Farsaci, B., Kwilas, A. R., and Gameiro, S. R.
(2012). The tipping point for combination therapy: cancer vaccines with
radiation, chemotherapy, or targeted small molecule inhibitors. Semin. Oncol.
39, 323–339. doi: 10.1053/j.seminoncol.2012.02.006
Iwai, L. K., Payne, L. S., Luczynski, M. T., Chang, F., Xu, H., Clinton, R. W.,
et al. (2013). Phosphoproteomics of collagen receptor networks reveals SHP-2
phosphorylation downstream of wild-type DDR2 and its lung cancer mutants.
Biochem. J. 454, 501–513. doi: 10.1042/BJ20121750
Kwilas, A.R., Donahue, R.N., Bernstein, M.B., and Hodge, J.W. (2012). In the field:
exploiting the untapped potential of immunogenic modulation by radiation in
combination with immunotherapy for the treatment of cancer. Front. Oncol.
2:104. doi: 10.3389/fonc.2012.00104
Leitinger, B. (2014). Discoidin domain receptor functions in physiological and
pathological conditions. Int. Rev. Cell Mol. Biol. 310, 39–87. doi: 10.1016/B978-
0-12-800180-6.00002-5
Marquez, J., and Olaso, E. (2014). Role of discoidin domain receptor 2 in wound
healing. Histol. Histopathol. 29, 1355–1364. doi: 10.14670/HH-29.1355
Ramos, P., and Bentires-Alj, M. (2015). Mechanism-based cancer therapy:
resistance to therapy, therapy for resistance. Oncogene 34, 3617–3626. doi:
10.1038/onc.2014.314
Ren, T., Zhang, W., Liu, X., Zhao, H., Zhang, J., Zhang, J., et al. (2014).
Discoidin domain receptor 2 (DDR2) promotes breast cancer cell
metastasis and the mechanism implicates epithelial-mesenchymal
transition programme under hypoxia. J. Pathol. 234, 526–537. doi: 10.1002/
path.4415
Semenova, E. A., Nagel, R., and Berns, A. (2015). Origins, genetic landscape, and
emerging therapies of small cell lung cancer. Genes Dev. 29, 1447–1462. doi:
10.1101/gad.263145.115
Valiathan, R. R., Marco, M., Leitinger, B., Kleer, C. G., and Fridman, R.
(2012). Discoidin domain receptor tyrosine kinases: new players in cancer
progression. Cancer Metastasis Rev. 31, 295–321. doi: 10.1007/s10555-012-
9346-z
Conflict of Interest Statement: The authors declare that the research was
conducted in the absence of any commercial or financial relationships that could
be construed as a potential conflict of interest.
Copyright © 2016 Rammal, Saby, Magnien, Van-Gulick, Garnotel, Buache, El
Btaouri, Jeannesson and Morjani. This is an open-access article distributed
under the terms of the Creative Commons Attribution License (CC BY). The
use, distribution or reproduction in other forums is permitted, provided the
original author(s) or licensor are credited and that the original publication in
this journal is cited, in accordance with accepted academic practice. No use,
distribution or reproduction is permitted which does not comply with these
terms.
Frontiers in Pharmacology | www.frontiersin.org 2 September 2016 | Volume 7 | Article 346
